ICHOM-INTERN L CONSORTIUM ON HEALTH OUTCOMES MEASUREMENT



Similar documents
Measuring Outcomes. The Key to Value-Based Health Care

International Consortium for Health Outcomes Measurement. Dr James Kent, BCG Dr Tom Kelley, ICHOM

Questions to ask my doctor: About prostate cancer

The Business of Prostate Cancer Care: A Clinician-Researcher s Perspective

Questions to Ask My Doctor About Prostate Cancer

FIVE YEAR REPORT. Victorian Prostate Cancer Clinical Registry

Outcome measurement International perspective. 7 th February 2014

PROSTATE CANCER. Get the facts, know your options. Samay Jain, MD, Assistant Professor,The University of Toledo Chief, Division of Urologic Oncology

SRO Tutorial: Prostate Cancer Treatment Options

Radiation Therapy for Prostate Cancer: Treatment options and future directions

APCCR- Prostate Cancer Registry

Early Prostate Cancer: Questions and Answers. Key Points

to Know About Your Partner s

CMScript. Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014

Prostate Cancer. Treatments as unique as you are

Cancer research in the Midland Region the prostate and bowel cancer projects

Thomas A. Kollmorgen, M.D. Oregon Urology Institute

Precise, Minimally Invasive Prostate Cancer Removal

Proton Therapy for Prostate Cancer: Your Questions, Our Answers.

Beyond the PSA: Genomic Testing in Localized Prostate Cancer

Analysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data

Treating Prostate Cancer

Focal therapy for prostate cancer: seriously or seriously? Disclosures

7. Prostate cancer in PSA relapse

Bard: Prostate Cancer Treatment. Bard: Pelvic Organ Prolapse. Prostate Cancer. An overview of. Treatment. Prolapse. Information and Answers

Understanding the. Controversies of. testosterone replacement. therapy in hypogonadal men with prostate cancer. controversies surrounding

PSA Screening for Prostate Cancer Information for Care Providers

These rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma.

Board of Member States ERN implementation strategies

SIOG Guidelines Update 2014 Prostate Cancer. Dr Helen Boyle Centre Léon Bérard SIOG meeting 25 October 2014,Lisbon

Oncology Annual Report: Prostate Cancer 2005 Update By: John Konefal, MD, Radiation Oncology

An Introduction to PROSTATE CANCER

A Woman s Guide to Prostate Cancer Treatment

Treating Localized Prostate Cancer A Review of the Research for Adults

Screening for Prostate Cancer

TO SCREEN OR NOT TO SCREEN: THE PROSTATE CANCER

855-DRSAMADI or

OUR MISSION. Measuring. Cataracts. Visual acuity. Level of urinary incontinence

Historical Basis for Concern

Prostate cancer. Christopher Eden. The Royal Surrey County Hospital, Guildford & The Hampshire Clinic, Old Basing.

Prostate Cancer. There is no known association with an enlarged prostate or benign prostatic hyperplasia (BPH).

Prostate Cancer. Patient Information

The Science behind Proton Beam Therapy

Clinical Trials and Radiation Treatment. Gerard Morton Odette Cancer Centre Sunnybrook Research Institute University of Toronto

Prostate Cancer Treatment: What s Best for You?

Prostate Cancer Screening. A Decision Guide

FAQ About Prostate Cancer Treatment and SpaceOAR System

Prostate cancer screening. It s YOUR decision!

PSA screening in asymptomatic men the debate continues keyword: psa

AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options

A918: Prostate: adenocarcinoma

Mortality from Prostate Cancer Urological Cancers SSCRG

HEALTH NEWS PROSTATE CANCER THE PROSTATE

Urinary Incontinence Control using External Urethral Compression Devices (Clamps)

Prostate Cancer Action Plan: Choosing the treatment that s right for you

Value-Based Health Care Delivery: Creating an Action-Research Agenda

Prostate Cancer Screening. A Decision Guide for African Americans

da Vinci Prostatectomy Information Guide (Robotically-Assisted Radical Prostatectomy)

Wait Times for Priority Procedures in Canada, 2014

ADVANCING MEASUREMENT OF PATIENT- CENTERED OUTCOMES AND QUALITY METRICS WITH ELECTRONIC HEALTH RECORDS

Radiation Therapy in Prostate Cancer Current Status and New Advances

ACCEPTED MANUSCRIPT. Understanding the performance of active surveillance selection criteria in diverse urology practices

Prostate cancer is the most common cause of death from cancer in men over age 75. Prostate cancer is rarely found in men younger than 40.

The PSA Test for Prostate Cancer Screening:

Prostate Cancer Guide. A resource to help answer your questions about prostate cancer

How To Improve Health Care Quality

Prostate Massage Orgasm Techniques -->> Enter Here

Radiation Therapy in Prostate Cancer Current Status and New Advances

DIAGNOSIS OF PROSTATE CANCER

The PSA Controversy: Defining It, Discussing It, and Coping With It

Kegel Exercises for Men

sexual after Being prostate cancer... Manitoba Prostate Centre Visit our website at

Prostate Cancer. What is prostate cancer?

HEALTH CARE DATA IN QATAR

Transcription:

Poster Session HRT11420 Innovation Awards November 2014 Melbourne ICHOM-INTERN L CONSORTIUM ON HEALTH OUTCOMES MEASUREMENT Jeremy Millar AlfredHealth Monash University The Health Roundtable

Key problem: There is enormous variation in health outcomes for patients with health problems managed even in developed countries around the world and this is enormously costly in money and happiness; and yet the human impact is poorly measured and tracked so we fail to move towards highvalue health care Aim: Align international experts on a list of outcomes domains, baseline and risk adjustment factors in order to pool de-identified patient-level data together to analyze variations What: Brought together experts in 4 common health conditions including prostate cancer to develop and promote standard data sets; pool and benchmark these; note variation and spread best practice First datasets published; developing implementation program The Health Roundtable

On outcomes that matter to prostate cancer patients, there is dramatic variation and strong potential for improvement % 100 93.5 90 80 75.5 80.0 70 60 50 56.7 50.0 40 34.7 30 20 10 0 1 yr full continence Germany Sweden Best-in-class: Martini Klinik 1 yr urinary incontinence 4.5 10.0 1 yr severe urinary incontinence 0.4 Swedish data rough estimates from graphs Source: National quality report for the year of diagnosis 2012 from the National Prostate Cancer Register (NPCR) Sweden, Martini Klinik, BARMER GEK Report Krankenhaus 2012, Patient-reported outcomes (EORTC-PSM), 1 year after treatment, 2010

Analyzing variation globally will open greater opportunities for learning and improvement Align on standard metrics of success Align international experts on a list of outcomes domains, baseline and risk adjustment factors Provide clear and unambiguous definitions to track these standard metrics across countries and care setting Implement systematic measurement Develop guidelines and tools to facilitate the adoption of the Standard Set Identify IT solutions and develop "ready-to-use" solutions (with instruments and questionnaires ) Support centers in the adoption of the Sets Analyze global data, identify and share best practices Pool de-identified patient-level data together to analyze variations Use "Positive Deviance" methodology to understand the reasons of positive variations and best practices Pilot best practices in a few centers to establish evidence Spread the best practices

Systematic outcome measurement allows rapid identification and spread of best practices 6 months for full adoption of FFLU at MK The individual results of every Martini Klinik surgeon are tracked and compared to improve care early adopter 2 innovato r early adopter 1 Martini Klinik s diffusion of surgical innovation took 6 months, as compared to 15 years on average in the literature Source: Eur Urol 60 (2011): 320-329. FFLU: Full Functional Length Urethra

Outcome comparisons globally could improve the lives of 1000s of prostate cancer patients Improving the number of patients fully continent after a year: example for the US 100,000 80,000 60,000 40,000 20,000 0 (based on 88,000 prostatectomies per year) 50,160 +32,560 82,720 Befor Afte (57%) e (94%) r A collaborative built around outcomes measurement will allow us to identify and understand sources of variation Over time, through shared learning and knowledge exchange, we can reduce this variation and improve care for patients around the world In the United States, ~ 88,000 prostatectomies performed in 2008 If we assume that the average 1- year continence rate in the US is similar to Germany (57%), bringing the US average to the rate of Martini Klinik (94%) would mean that an additional 32,000+ American men would regain full continence

ICHOM built the "common language" of outcomes measurement for prostate cancer Example for Localized Prostate Cancer Treatment approaches covered Watchful waiting Active surveillance Prostatectomy External beam radiation therapy Brachytherapy Androgen Deprivation Treatment Other A "reference guide" contains all the details to measure in a standard way the outcomes recommended (link to download) 2013 ICHOM. All rights reserved. When using this set of outcomes, or quoting therefrom, in any way, we solely require that you always make a reference to ICHOM a s the source so that this organization can continue i ts work to define more standard outcome sets.

Several innovators are moving forward with implementation A few examples for Prostate Cancer MD Anderson (US) Dana Farber/Brigham and Women s Hospital (US) Martini Klinik (DE) Hamburg Brachytherapy (DE) Irish Prostate Cancer Outcomes Registry (IE) Australian Prostate Cancer Clinical Registry (AU) And many more have expressed interest Facilitating adoption and capturing learning at leading centers, while ramping up new contributors would accelerate the impact of outcomes

OUTCOMES SO FAR The Health Roundtable

LESSONS LEARNT Michael Porter s proposition of aligning all stakeholders on maximising value of health care, and of facilitating this by measurement of outcomes that matter to patients needs to be translated into real-word systems Datasets designed to drive institutional improvement are different from Registries designed to propel systematic changes: the first is bottom up & the 2 nd top-down Professional engagement, institutional support, and governance policy changes are all necessary for these efforts but each not sufficient to achieve change The Health Roundtable

A/Professor Jeremy Millar jeremy.millar@monash.edu +61 419 770 239 A/Professor Sue Evans sue.evans@monash.edu +61 408 510 921 The Health Roundtable